Haemophilia

Article	Citations
WFH Guidelines for the Management of Hemophilia, 3rd edition	1003
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A	68
The role of telemedicine in the delivery of health care in the COVID‐19 pandemic	53
Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US	41
Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring	41
Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC	36
European principles of care for women and girls with inherited bleeding disorders	35
Low immunogenicity of emicizumab in persons with haemophilia A	32
Telehealth for delivery of haemophilia comprehensive care during the COVID‐19 pandemic	31
Genetic causes of haemophilia in women and girls	30
Women and girls with haemophilia: Lessons learned	29
Emicizumab state‐of‐the‐art update	29
Bleeding of unknown cause and unclassified bleeding disorders; diagnosis, pathophysiology and management	28
Evidence of a disability paradox in patient‐reported outcomes in haemophilia	28
Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study	27
Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data	27
Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A	27
Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate)	26
Off‐label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature	24
Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?	23
Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays	23
Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel	23
The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies	23
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study	23
Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery	22

Non‐severe haemophilia: Is it benign? – Insights from the PROBE study	21
The Function of extravascular coagulation factor IX in haemostasis	21
Comparison of bypassing agents in patients on emicizumab using global hemostasis assays	20
Haemophilia care in China: Achievements in the past decade	20
Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?	20
Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and	20
Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real‐world cases to support shared decision‐making	19
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update	19
An exploration of why men with severe haemophilia might not want gene therapy: The exigency study	19
Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study	19
An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies	19
How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types	18
Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States	18
Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis	17
Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment	17
Gene therapy: Practical aspects of implementation	17
Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS	17
Registry of patients with congenital bleeding disorders and COVID‐19 in Madrid	17
Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review	17
In‐hospital management of persons with haemophilia and COVID‐19: Practical guidance	16
Joint replacement for the management of haemophilic arthropathy in patients with inhibitors: A long‐term experience at a single Haemophilia centre	16
Pathological coagulation parameters in as many as 54 patients with autoimmune acquired factor XIII deficiency due to anti–factor XIII autoantibodies	16
Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study	16
The 2021 von Willebrand disease guidelines: Clarity and controversy	16
Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors	16
Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU	15
Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues	15
Hemophilia gene therapy—New country initiatives	15
Effectiveness of monthly low dose emicizumab prophylaxis without 4‐week loading doses among patients with haemophilia A with and without inhibitors: A case series report	15
Parental perspectives on gene therapy for children with haemophilia: The Exigency study	14
Comparative analysis of the pivotal studies of extended half‐life recombinant FVIII products for treatment of haemophilia A	14
Natural anticoagulants: A missing link in mild to moderate bleeding tendencies	13
Managing women‐specific bleeding in inherited bleeding disorders: A multidisciplinary approach	13
The relationship between chronic pain and psychosocial aspects in patients with haemophilic arthropathy. A cross‐sectional study	13
Real‐world cost estimates of initiating emicizumab in US patients with haemophilia A	13
Prophylaxis in children with haemophilia in an evolving treatment landscape	13
Detection and evaluation of haemophilic arthropathy: Which tools may be considered more reliable	13
Clinical assessment and point of care ultrasonography: How to diagnose haemophilic synovitis	13
Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study	13
Diagnosis of von Willebrand disease: An assessment of the quality of testing in North American laboratories	13
Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study	13
Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey	13
POSTER ABSTRACTS	13
Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India	13
Management of COVID‐19‐associated coagulopathy in persons with haemophilia	13
Efficacy and safety of fibrinogen concentrate for on‐demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency	13
Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States	13
Impact of haemophilia on patients with mild‐to‐moderate disease: Results from the P‐FiQ and B‐HERO‐S studies	13
Lower physical activity and altered body composition in patients with haemophilia compared with healthy controls	13
Activity and participation in haemophiliacs: Item response modelling based on international classification of functioning, disability and health	12

Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors	12
Feasibility and outcomes of low‐dose and low‐frequency prophylaxis with recombinant extended half‐life products (Fc‐rFVIII and Fc‐rFIX) in Ivorian children with hemophilia: Two‐year experience in the	12
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study	12
Risk of deep venous thrombosis after total knee arthroplasty in patients with haemophilia A	12
Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise	12
Assessing the test–retest reliability and smallest detectable change of the Haemophilia Activities List	12
Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France	12
Therapeutic and technological advancements in haemophilia care: Quantum leaps forward	12
Gaining more insight into ankle pain in haemophilia: A study exploring pain, structural and functional evaluation of the ankle joint	12
The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole F8 gene sequencing and functional assays	12
Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review	12
The B‐Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B	12
The rising incidence of acquired haemophilia A in Germany	12
Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC	11
A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen	11
Alternative payment models for durable and potentially curative therapies: The case of gene therapy for haemophilia A	11
Identification of new F8 deep intronic variations in patients with haemophilia A	11
3D gait analysis, haemophilia joint health score, leg muscle laterality and biomarkers of joint damage: A cross‐sectional comparative assessment of haemophilic arthropathy	11
Gynaecological management of women with inherited bleeding disorders. A UK Haemophilia Centres Doctors' Organisation Guideline	11
Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis	11
Patients’ and parents’ satisfaction with, and preference for, haemophilia A treatments: a cross‐sectional, multicentre, observational study	11
A case of acquired haemophilia A in a 70‐year‐old post COVID‐19 vaccine	11
Cost‐utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea	11
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with hae	11
Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey	11
Identified unmet needs and proposed solutions in mild‐to‐moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts	11
All‐cause mortality and causes of death in persons with haemophilia: A systematic review and meta‐analysis	11
Osteoporosis management and falls prevention in patients with haemophilia: Review of haemophilia guidelines	10
Exercise capacity in people with haemophilia: A systematic review	10
Building the blueprint: Formulating a community‐generated national plan for future research in inherited bleeding disorders	10
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study	10
Quantitative measurements of haemophilic joint tissues by point‐of‐care musculoskeletal ultrasound: Associations with clinical and functional joint outcome parameters	10
Promoting physical activity for people with haemophilia in the age of new treatments	10
Complications of total knee arthroplasty in patients with haemophilia compared with osteoarthritis and rheumatoid arthritis: A 20‐year single‐surgeon cohort	10
Validation of a new instrument to measure disease‐related distress among patients with haemophilia	10
Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK	10
Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years	10
Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature	10
Abstract	10
Most subjectively affected joints in patients with haemophilia – what has changed after 20 years in Germany?	10
Do we need all that emicizumab?	10
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia	10
Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 2022	10
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies	10
Big picture initiatives in bleeding disorders	10
Low rate of subclinical venous thrombosis in patients with haemophilia undergoing major orthopaedic surgery in the absence of pharmacological thromboprophylaxis	9
Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD‐US system	9
Haemophilia gene therapy—Update on new country initiatives	9
POSTER PRESENTATIONS	9
Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes	9
An evaluation of PROMIS health domains in adults with haemophilia: A cross‐sectional study	9
Determining meaningful health‐related quality‐of‐life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL)	9
Effects of a non‐pharmacological approach for chronic pain management in patients with haemophilia: efficacy of cognitive‐behavioural therapy associated with physiotherapy	9
Descriptive analysis of bleeding symptoms in haemophilia carriers enrolled in the ATHNdataset	9
Pharmacokinetic‐guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A	9
Real‐world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure:	9
Successful correction of factor V deficiency of patient‐derived iPSCs by CRISPR/Cas9‐mediated gene editing	9
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A	9
Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy	9
Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders	9
Effectiveness of emicizumab in preventing life‐threatening bleeding complications in type 3 von Willebrand disease with inhibitors: A paediatric report	9
Addressing patient education priorities in the era of gene therapy for haemophilia: Towards evidence‐informed shared decision‐making	9
Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study	9
Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary	8
Pain, depression and anxiety in people with haemophilia from three Nordic countries: Cross‐sectional survey data from the MIND study	8
Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors	8
COVID‐19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery	8
Recurrence of a high‐titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis	8
How to assess, detect, and manage joint involvement in the era of transformational therapies: Role of point‐of‐care ultrasound	8
Towards novel treatment options in von Willebrand disease	8
Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A	8
Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis	8
Real‐world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow‐up in a national adult cohort	8
Validation of the pictorial blood loss assessment chart using modern sanitary products	8
Acquired bleeding disorders	8
Drug‐associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database	8
Gene therapy preferences and informed decision‐making: Results from a National Hemophilia Foundation Community Voices in research survey	8
Health technology assessment for gene therapies in haemophilia	8
Acquired haemophilia A after alemtuzumab therapy	8
Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics	8

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A	8
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Gro	8
Clinical and patient reported outcome in total ankle replacement compared to ankle fusion in end‐stage haemophilic arthropathy	8
Reimbursing the value of gene therapy care in an era of uncertainty	8
Depression and anxiety in persons with Von Willebrand disease	8
Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline	8
Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single‐centre experience	8
The effectiveness of manual therapy in addition to passive stretching exercises in the treatment of patients with haemophilic knee arthropathy: A randomized, single‐blind clinical trial	8
A comparison of MyPKFiT and WAPPS‐Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa	8
Unravelling the knowledge, beliefs, behaviours and concerns of Persons with Haemophilia and their carriers in Senegal	8
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B‐LONG using haemophilia‐specific quality of life questionnaires	8
Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition	8
Biomarkers of bone disease in persons with haemophilia	8
Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy	7
Sports participation of patients with haemophilia in the COVID‐19 era: The Dutch experience	7
Thrombomodulin in patients with mild to moderate bleeding tendency	7
Development of a haemophilia A gene therapy shared decision‐making tool for clinicians	7
Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma	7
Global epidemiology of factor XI deficiency: A targeted review of the literature and foundation reports	7
The GOAL‐Hēm journey: Shared decision making and patient‐centred outcomes	7
Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view	7
Impact of COVID‐19 pandemic on mental health of patients with inherited bleeding disorders in Germany	7
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?	7
Patient satisfaction with US Hemophilia Treatment Center Care, Teams and Services: The First National Survey	7
Comparison of free‐living physical activity measurements between ActiGraph GT3X‐BT and Fitbit Charge 3 in young people with haemophilia	7
The views of women with bleeding disorders: Results from the Cinderella study	7
Adherence to prophylaxis and its association with activation of self‐management and treatment satisfaction	7
Association of factor expression levels with annual bleeding rate in people with haemophilia B	7
Ultrasound and patient self‐imaging in hemophilia	7
Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII‐free emicizumab therapy	7
Humanistic burden of problem joints for children and adults with haemophilia	7
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B	7
Single centre, real‐world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery	7
Thromboelastometry detects enhancement of coagulation in blood by emicizumab via intrinsic pathway	7
The role of total ankle replacement in patients with haemophilia and end‐stage ankle arthropathy: A review	7
Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab	7
Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia	7
Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures	7
Examining patient and professional perspectives in the UK for gene therapy in haemophilia	7
Clinical characteristics and surgical treatment of haemophilic pseudotumor: A retrospective analysis of thirty‐four patients	7
Mutation analysis in the F8 gene in 485 families with haemophilia A and prenatal diagnosis in China	7
Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A	7
Pharmacokinetic, efficacy and safety evaluation of B‐domain‐deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A	7
Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency	7
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors	6
Acupuncture as a therapeutic resource for treatment of chronic pain in people with haemophilia	6
Effectiveness of physical exercise on postural balance in patients with haemophilia: A systematic review	6
Safety of intramuscular COVID‐19 vaccination in patients with haemophilia	6
Bleeding with iron deposition and vascular remodelling in subchondral cysts: A newly discovered feature unique to haemophilic arthropathy	6
Limited sampling strategies for accurate determination of extended half‐life factor VIII pharmacokinetics in severe haemophilia A patients	6
Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database	6
ADAMTS‐4 as a possible distinguishing indicator between osteoarthritis and haemophilic arthropathy	6
The effects of manual therapy on musculoskeletal system, functional level, joint health and kinesiophobia in young adults with severe haemophilia: A randomized pilot study	6
Changes in pain profile of patients with haemophilia during 1‐year follow‐up	6
Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B‐NORD study	6
Patient‐reported outcomes in autosomal inherited bleeding disorders: A systematic literature review	6
Early wound complications after orthopaedic surgery for haemophilia: What can we do more	6
Patient and caregiver preferences for haemophilia A treatments: A discrete choice experiment	6
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors	6
Treatment preferences in people with haemophilia A or caregivers of people with haemophilia A: A discrete choice experiment	6
Prevalence and risk factors for hepatocellular carcinoma in individuals with haemophilia in the era of direct‐acting antiviral agents: A national inpatient sample study	6
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single‐institution experience	6
Gene therapy – are we ready now?	6
Severe haemophilia A children on low‐dose tertiary prophylaxis showed less joint deterioration and better maintenance of functional independence than children on on‐demand treatment: A 6‐year follow‐u	6
Bleeding complications during pregnancy and delivery in haemophilia carriers and their neonates in Western France: An observational study	6
Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres	6
Ultrasound and magnetic resonance imaging for the detection of blood: An ex‐vivo study	6
How mild is mild haemophilia?	6
Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high‐dose bypassing agents in the HAVEN 1 study	6
Implications of haemophilia gene therapy for the changing role of the multidisciplinary team	6
Autoimmune acquired factor XIII deficiency in Japan 2021 update: Focused on annual incidence and clinical features	6
The societal burden of haemophilia A. I – A snapshot of haemophilia A in Australia and beyond	6
Optimal trough levels in haemophilia B: Raising expectations	6
IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy	6
Shortening the Haemophilia Activities List (HAL) from 42 items to 18 items	6
Approximation of emicizumab plasma levels in emergency situations. A practical approach	6
Aerobic exercise in patients with haemophilia: A systematic review on safety, feasibility and health effects	6
Biomarkers and immunological parameters in haemophilia and rheumatoid arthritis patients: a comparative multiplexing laboratory study	6
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow‐up from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO)	6
Real‐world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes	6
Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural)	6
Platelet function testing: Current practice among clinical centres in Northern Europe	6
A phase IV, multicentre, open‐label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures	6
Pain memories: A new concept to consider in the management of chronic pain in people with haemophilia	6
Endothelial dysfunction and atherosclerosis related miRNA‐expression in patients with haemophilia	5
Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders	5
Synovitis and joint health in patients with haemophilia: Statements from a European e‐Delphi consensus study	5
Isokinetic knee strength deficit in patients with moderate haemophilia	5
Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease	5
Physiotherapy after COVID‐19—"Zoom or room"	5
Preoperative bleeding risk assessment with ISTH‐BAT and laboratory tests in patients undergoing elective surgery: A prospective cohort study	5
Dental habits and oral health in children and adolescents with bleeding disorders: A single‐institution cross‐sectional study	5
Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature	5
Clinical, economic, and health‐related quality of life burden associated with von Willebrand disease in adults and children: Systematic and targeted literature reviews	5
Demographics, clinical profile and treatment landscape of patients with haemophilia B in China	5